Compare SEMR & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEMR | ZYME |
|---|---|---|
| Founded | 2008 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2021 | 2017 |
| Metric | SEMR | ZYME |
|---|---|---|
| Price | $11.81 | $23.07 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $10.00 | ★ $32.75 |
| AVG Volume (30 Days) | ★ 1.8M | 594.4K |
| Earning Date | 03-04-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $428,627,000.00 | $134,481,000.00 |
| Revenue This Year | $20.35 | $63.10 |
| Revenue Next Year | $14.87 | $93.26 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 19.87 | ★ 116.21 |
| 52 Week Low | $6.56 | $9.03 |
| 52 Week High | $18.01 | $28.49 |
| Indicator | SEMR | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 51.11 | 48.12 |
| Support Level | $11.81 | $22.07 |
| Resistance Level | $11.88 | $23.52 |
| Average True Range (ATR) | 0.03 | 0.88 |
| MACD | -0.03 | 0.09 |
| Stochastic Oscillator | 4.17 | 60.44 |
SEMrush Holdings Inc is engaged in the online visibility management software-as-a-service (SaaS) platform. Its platform utilizes data and intelligence at the core surrounded by AI-powered interconnected hubs focused on search engine optimization, paid advertising, social media management, local marketing, brand marketing, and content marketing Geographically, it generates revenues from the United States, the UK, and Others.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.